Yposkesi, an SK pharmteco company, is one of Europe’s largest Contract Development and Manufacturing Organizations (CDMO) for gene therapy viral vector manufacturing. A one-stop shop for biotech and pharmaceutical companies seeking to advance clinical trials and commercialize new Advanced Therapy Medicinal Products (ATMPs), Yposkesi offers a full range of services in lentiviral vectors and AAV (Adeno-Associated Virus) cGMP manufacturing. Within its current 50,000 ft2 (approx. 5,000 m2) facility, Yposkesi operates multiple manufacturing suites for bulk drug substance (up to 1,000 L) and fill and finish to support the growing demand for late-phase projects. In 2023, Yposkesi will bring online additional capacity by increasing its global footprint to 100,000 ft2 (approx. 10,000 m2) with a second large-scale facility designed for EMA and FDA compliance. Yposkesi’s investment in innovation ensures that its bioprocessing platforms deliver high quality gene-modified cell therapies and in vivo gene therapy projects. Yposkesi’s staff of ~200 employees is located on the Genopole Campus in Corbeil-Essonnes (South of Paris), France.